INTERNATIONAL BIOTECHNOLOGY TRUST PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 616 GBX | +1.65% |
|
+0.98% | -4.05% |
Valuation
| Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 255.3 | 244.2 | 280.6 | 301.9 | 266.2 | 253.2 |
| Enterprise Value (EV) 1 | 255.6 | 243.3 | 298.4 | 322.2 | 306.2 | 285.7 |
| P/E ratio | 12.8 x | -13.7 x | 5.26 x | 10.6 x | -11.9 x | 38.4 x |
| Yield | 3.97% | 4.4% | 3.4% | 3.89% | 4.83% | 4.38% |
| Capitalization / Revenue | 11.6 x | -18.4 x | 5.08 x | 9.43 x | -19.6 x | 24.2 x |
| EV / Revenue | 11.6 x | -18.3 x | 5.4 x | 10.1 x | -22.5 x | 27.3 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | 149 x | -19.9 x | 8.7 x | 17.7 x | -12.8 x | 20.6 x |
| FCF Yield | 0.67% | -5.03% | 11.5% | 5.64% | -7.81% | 4.86% |
| Price to Book | 0.97 x | 1.02 x | 0.99 x | 0.93 x | 0.93 x | 0.94 x |
| Nbr of stocks (in thousands) | 37,548 | 38,398 | 38,437 | 41,384 | 40,863 | 39,318 |
| Reference price 2 | 6.800 | 6.360 | 7.300 | 7.295 | 6.515 | 6.440 |
| Announcement Date | 10/30/18 | 12/19/19 | 11/2/20 | 12/20/21 | 11/1/22 | 11/7/23 |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 21.97 | -13.27 | 55.26 | 32.03 | -13.58 | 10.47 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | 19.18 | -16.71 | 52.09 | 28.2 | -17.28 | 6.586 |
| Operating Margin | 87.28% | 125.94% | 94.26% | 88.04% | 127.23% | 62.91% |
| Earnings before Tax (EBT) 1 | 20.01 | -17.44 | 53.59 | 28.05 | -22.32 | 6.935 |
| Net income 1 | 19.96 | -17.54 | 53.42 | 27.88 | -22.47 | 6.813 |
| Net margin | 90.85% | 132.17% | 96.68% | 87.06% | 165.45% | 65.08% |
| EPS 2 | 0.5316 | -0.4634 | 1.389 | 0.6886 | -0.5472 | 0.1679 |
| Free Cash Flow 1 | 1.711 | -12.23 | 34.28 | 18.18 | -23.9 | 13.89 |
| FCF margin | 7.79% | 92.17% | 62.03% | 56.77% | 175.96% | 132.67% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | 8.57% | - | 64.17% | 65.21% | - | 203.86% |
| Dividend per Share 2 | 0.2700 | 0.2800 | 0.2480 | 0.2840 | 0.3145 | 0.2820 |
| Announcement Date | 10/30/18 | 12/19/19 | 11/2/20 | 12/20/21 | 11/1/22 | 11/7/23 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.23 | - | 17.8 | 20.3 | 40 | 32.5 |
| Net Cash position 1 | - | 0.89 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 1.71 | -12.2 | 34.3 | 18.2 | -23.9 | 13.9 |
| ROE (net income / shareholders' equity) | 7.75% | -6.99% | 20.4% | 9.18% | -7.38% | 2.45% |
| ROA (Net income/ Total Assets) | 4.48% | -4.14% | 12% | 5.42% | -3.2% | 1.3% |
| Assets 1 | 445.9 | 423.2 | 446 | 514.6 | 702 | 522.9 |
| Book Value Per Share 2 | 6.990 | 6.240 | 7.390 | 7.820 | 6.970 | 6.880 |
| Cash Flow per Share 2 | 0 | 0.0200 | 0.0100 | 0.0400 | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 10/30/18 | 12/19/19 | 11/2/20 | 12/20/21 | 11/1/22 | 11/7/23 |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.16
Average target price
-
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.05% | 290M | |
| +3.27% | 14.32B | |
| +3.12% | 6.21B | |
| +12.72% | 4.4B | |
| +10.97% | 4.36B | |
| -7.52% | 4B | |
| +3.61% | 3.51B | |
| +8.55% | 3.22B | |
| +7.91% | 3.06B | |
| -1.91% | 2.77B |
- Stock Market
- Equities
- IBT Stock
- Financials International Biotechnology Trust plc
